Today: 30 April 2026
Under Armour stock steadies in premarket after Fairfax lifts stake to 16.1% in fresh buys
31 December 2025
2 mins read

Under Armour stock steadies in premarket after Fairfax lifts stake to 16.1% in fresh buys

NEW YORK, December 31, 2025, 05:37 ET — Premarket

  • Under Armour Class A shares (UAA) were flat in premarket trading after a sharp jump in the prior session.
  • Fairfax-linked entities disclosed about $71 million in late-December purchases across Under Armour’s two share classes, a Form 4 showed.
  • A Schedule 13G filing showed Fairfax and affiliates now hold 16.1% of Under Armour’s Class A stock.

Under Armour’s Class A shares were flat in premarket trading on Wednesday at $5.14, after surging in the prior session on disclosures that Fairfax Financial and related entities had been buying the sportswear maker’s stock.

The buying matters because it comes with Under Armour still trying to rebuild investor confidence after a long stretch of choppy sales trends and restructuring actions, while its stock trades far below its highs of the past year.

Large purchases by a “10% owner” — SEC shorthand for a shareholder with at least a 10% stake — often draw traders’ attention because U.S. rules require that holder to disclose buying and selling quickly, reducing uncertainty about who is accumulating shares. SEC

In a filed late Monday, Fairfax-controlled entities reported buying a combined 15.68 million Under Armour shares between Dec. 22 and Dec. 29 for about $71.0 million, at weighted-average prices ranging roughly from $4.36 to $4.73.

The filing showed Fairfax and affiliates ended that period with 30.45 million Class A shares and 7.78 million Class C shares held indirectly through wholly owned subsidiaries.

A separate amendment said Fairfax-linked reporting persons beneficially owned 30.45 million Class A shares, representing 16.1% of the class based on shares outstanding as of Oct. 31, 2025. (A Schedule 13G is the SEC filing large investors typically use to disclose stakes when they say they are not seeking control.)

In Tuesday’s regular session, Class A shares (UAA) closed up 7.53% at $5.14, while Class C shares (UA) gained 8.59% to $4.93; early Wednesday, UA slipped 0.61% in premarket to $4.90.

Under Armour’s move outpaced larger athleticwear names on the day, with Nike ending slightly lower while Deckers rose modestly, according to MarketWatch data.

Under Armour has two publicly traded share classes on the NYSE — UAA (Class A) and UA (Class C) — and both have been hovering near the lower end of their 52-week range, after touching a low of $4.13 and a high of $8.72.

The Baltimore-based company has been working through a turnaround under founder Kevin Plank, who returned as CEO in April 2024. “Eighteen months into its turnaround plan, Under Armour appears to be struggling to navigate both a challenging external environment and internal missteps,” said eMarketer analyst Sky Canaves. (Story: Reuters, Nov. 6) Reuters+1

Credit markets are also on watch: S&P Global placed Under Armour’s ratings on downgrade watch in late November, citing continued restructuring challenges and sales declines, and said it would resolve the watch placement within about 90 days depending in part on holiday sales and profitability. (Story: )

On the Street, Under Armour’s analyst consensus remains cautious, with a “Hold” rating and an average 12-month price target of about $6.18, according to StockAnalysis. StockAnalysis

For the session ahead, traders will watch whether the insider buying triggers follow-on stake disclosures and whether UAA can hold above the $5 level after Tuesday’s spike; the next quarterly results are not yet company-confirmed, but MarketBeat estimates a Feb. 5 report before the open based on past patterns. (Calendar: )

Stock Market Today

  • Amazon Raises Price Target After Strong Q1 Fueled by AWS Growth
    April 29, 2026, 8:42 PM EDT. Amazon shares jumped following a first-quarter performance surpassing expectations, with revenue up 17% year-on-year to $181.52 billion, driven by a 28.4% surge in Amazon Web Services (AWS) revenue. Earnings per share soared 75% to $2.78, boosted by a $16.8 billion non-operating gain linked to its Anthropic investment. Operating income grew 30% to $23.85 billion, reflecting efficiency gains across North America and international operations. AWS's rapid growth, alongside high-margin advertising and robust e-commerce logistics, underpinned optimism. The company raised its price target to $300 from $250, maintaining a buy-equivalent rating. AWS's portfolio of proprietary chips, including Graviton and Tranium, reached a $20 billion annual revenue run rate, underscoring Amazon's scaling infrastructure. The stock gained about 4% in after-hours trade, extending a strong run that saw a 26% rise in April to record highs.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Previous Story

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Ondas stock slips in premarket after 2x leveraged ONDS ETF launch sparks heavy trading
Next Story

Ondas stock slips in premarket after 2x leveraged ONDS ETF launch sparks heavy trading

Go toTop